Latest Licensing Agreements News

Wellnex Life Limited announces key board and management changes following its successful AIM Market dual listing, including the resignation of its Non-Executive Chairman and appointment of a joint CEO to drive growth.

Dimerix has received a US$30 million upfront payment from Amicus Therapeutics for exclusive US rights to DMX-200, a promising kidney disease therapy. The deal positions Dimerix for up to US$560 million in further milestones plus royalties, underpinning its global licensing strategy.

Unibail-Rodamco-Westfield and Cenomi Centers have entered a decade-long exclusive partnership to bring the Westfield brand to Saudi Arabia’s premier shopping centres, aiming to reshape retail experiences across the Kingdom’s largest cities.

Hazer Group has entered a binding six-year strategic alliance with global engineering leader KBR to exclusively market and license its methane pyrolysis technology, targeting the ammonia and methanol sectors. This partnership aims to accelerate commercialisation, expand global reach, and materially de-risk Hazer’s business plan.

AdAlta Limited has announced a pro rata renounceable rights offer to raise approximately $1.29 million, aiming to fund its strategic pivot towards licensing CAR-T cell therapies through its subsidiary AdCella. The offer includes new shares and options, underpinned by key insiders and an underwriting agreement.

AdAlta Limited has announced a renounceable rights issue to raise up to $1.3 million, aiming to accelerate its ‘East to West’ cellular immunotherapy strategy and explore new strategic options.

Dimerix Limited has announced a US licensing transaction for its Phase 3 asset DMX-200 targeting FSGS, alongside progress updates on its clinical trial. The move underscores the company’s push to address a rare kidney disease with no approved therapies.

Dimerix has inked an exclusive US licensing agreement with Amicus Therapeutics for DMX-200, a promising Phase 3 treatment for FSGS, unlocking $30 million upfront and up to $560 million in milestones.

Ovanti Limited has taken decisive steps to accelerate its US Buy Now Pay Later (BNPL) market entry, appointing an interim CEO and securing a pivotal 20-year licensing agreement with BNPLPay Protocol that offers low-cost funding and a significant revenue share.

Vectus Biosystems advances its lead fibrosis drug VB0004 with validated Phase I safety data and strategic cost reductions, while actively pursuing licensing partnerships in China.

Thrive Tribe Technologies has initiated a corporate restructure focused on revenue growth, appointed a seasoned COO, and rebranded its platform while securing venture debt funding to support expansion.

Dimerix Limited advances its Phase 3 kidney disease trial with FDA acceptance of proteinuria as a primary endpoint and clinches a lucrative licensing agreement in Japan worth up to AU$107 million plus royalties.